IIP
WST icon

Intermede Investment Partners’s West Pharmaceutical WST Stock Holding History

Intermede Investment Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-249,185
Closed -$74.8M – 34
2024
Q3 		$74.8M Buy
249,185
+53,851
+28% +$16.5M 1.56% 28
2024
Q2 		$64.3M Sell
195,334
-52,739
-21% -$18.6M 1.36% 29
2024
Q1 		$98.2M Buy
248,073
+42,536
+21% +$15.7M 2% 28
2023
Q4 		$72.4M Sell
205,537
-10,061
-5% -$3.56M 1.64% 26
2023
Q3 		$80.9M Sell
215,598
-57,699
-21% -$22.3M 2.07% 21
2023
Q2 		$105M Sell
273,297
-64,268
-19% -$23M 2.44% 22
2023
Q1 		$117M Buy
337,565
+1,415
+0.4% +$413K 2.87% 18
2022
Q4 		$79.1M Buy
336,150
+71,005
+27% +$16.8M 2.21% 23
2022
Q3 		$65.2M Buy
265,145
+13,027
+5% +$3.97M 1.83% 25
2022
Q2 		$76.2M Buy
252,118
+7,314
+3% +$2.38M 2.11% 22
2022
Q1 		$101M Buy
244,804
+16,805
+7% +$6.58M 2.35% 22
2021
Q4 		$107M Buy
227,999
+7,048
+3% +$3.03M 2.2% 25
2021
Q3 		$93.8M Sell
220,951
-1,931
-0.9% -$814K 2.16% 23
2021
Q2 		$80M Sell
222,882
-4,605
-2% -$1.52M 1.82% 26
2021
Q1 		$64.1M Sell
227,487
-20,800
-8% -$5.95M 1.64% 27
2020
Q4 		$70.3M Buy
248,287
+48,783
+24% +$13.7M 2.03% 24
2020
Q3 		$54.8M Sell
199,504
-16,772
-8% -$4.44M 2.29% 21
2020
Q2 		$49.1M Sell
216,276
-32,185
-13% -$6.32M 2.4% 20
2020
Q1 		$37.8M Sell
248,461
-4,204
-2% -$647K 2.23% 21
2019
Q4 		$38M Sell
252,665
-42,691
-14% -$6.22M 1.92% 23
2019
Q3 		$41.9M Sell
295,356
-3,584
-1% -$493K 2.33% 22
2019
Q2 		$37.4M Sell
298,940
-4,051
-1% -$478K 2.21% 22
2019
Q1 		$33.4M Buy
302,991
+36,520
+14% +$3.8M 2.08% 23
2018
Q4 		$26.1M Buy
266,471
+13,400
+5% +$1.45M 2.09% 24
2018
Q3 		$31.2M Buy
253,071
+10,078
+4% +$1.13M 2.34% 24
2018
Q2 		$24.1M Sell
242,993
-8,215
-3% -$756K 1.91% 25
2018
Q1 		$22.2M Buy
+251,208
New +$23.5M 1.9% 24

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Intermede Investment Partners's WST Position: Q4 2024 in Review

Intermede Investment Partners sold out of West Pharmaceutical (WST) in Q4 2024, closing a stake of 249,185 shares — an estimated $74.8M sold.

Intermede Investment Partners first reported a position in WST in Q1 2018 and held it in 27 quarters. The position peaked at $117M in Q1 2023. 747 funds tracked by Wall St. Rank hold WST as of Q4 2024.

  • Intermede Investment Partners reported no remaining West Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Intermede Investment Partners sold 249,185 West Pharmaceutical shares in Q4 2024, an estimated $74.8M.
  • Intermede Investment Partners first reported a position in West Pharmaceutical in Q1 2018 and held it in 27 quarters.
  • Intermede Investment Partners's West Pharmaceutical position peaked at $117M in Q1 2023.
  • 747 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2024.

Based on Intermede Investment Partners's 13F filing for Q4 2024, filed 10 Feb 2025.